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ABSTRACT
Objective: This study was carried out to assess the drug utilization pattern of calcium, Vitamin D supplements, and anti-osteoporosis drugs in patients 
with osteoporotic fracture in an Indian teaching hospital.
Methods: A cross-sectional study was carried out for 6 months in outpatients receiving treatment from the orthopedic department of an Indian 
teaching hospital. Demographic details, comorbidities, types of fracture, laboratory parameters, and drug therapy were collected from the patient 
case records who met the study criteria and documented in the data collection form. All the collected details were later analyzed using descriptive 
statistics.
Results: A total of 73 patient’s prescriptions were reviewed, in which 45.2% were male and 54.8% were female. Majority of the patients were in the 
age group of 50–60 years with mean age of 63.52±11.06 years. Hypertension (27.16%) was the highest comorbidity identified in the study followed 
by diabetes (18.51%) and coronary artery disease (14.81%). Of the total patients, 65.75% were prescribed with calcium and Vitamin D supplements 
and 2.73% received bisphosphonates.
Conclusion: The study shows the pattern of drug use in elderly with osteoporotic fractures. Since calcium and Vitamin D are vital for treating 
osteoporotic fractures, adequate monitoring of serum levels of calcium and Vitamin D3 may help to prescribe doses with desired need and safety level.
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INTRODUCTION
Osteoporosis is a major health concern worldwide among the 
aging individuals that has a remarkable financial impact on the 
society. Osteoporosis, meaning “porous bone,” is a skeletal disorder 
characterized by compromised bone strength with decreased 
bone mass and deterioration of bone microarchitecture, leading to 
increased bone fragility, predisposing a person to increased risk of 
fracture [1]. According to the World Health Organization criteria, 
osteoporosis is defined as a bone mineral density (BMD) that lies 
2.5 standard deviations (SDs) or more below the average value for 
young person (T-score of <−2.5 SD) [2]. Fractures associated with 
osteoporosis have a significant impact on patients’ quality of life 
and health-care costs, leading to increased risk for morbidity and 
mortality. The major risk factors that may lead to fractures are age, 
decreased BMD, low body mass index, a history of a prior fracture at a 
site characteristic for osteoporosis, a parental history of hip fracture, 
smoking, alcohol use, glucocorticoid use, and rheumatoid arthritis. 
Due to menopause, after the age of 50–55 years, women are more 
prone to fractures. Men are also at 25% fracture risk after they cross 
the age of 50 years [3,4].
General fracture prevention strategies include an increase in dietary 
calcium intake, a higher level of physical activities at all ages, reduction 
in the prevalence of smoking, decrease in alcohol consumption, fall 
prevention program, and hip protectors. The current management 
on osteoporosis includes comprehensive education for lifestyle 
modification, supplementation of calcium and Vitamin D, and anti-
osteoporosis drugs such as anti-resorptive and bone formation 
agents [5].
Calcium and Vitamin D supplements play a major role in treating 
osteoporosis and can reduce the risk of fracture. A study findings 
support a role for calcium and Vitamin D supplementation in 
osteoporosis treatment, as the diets of many osteoporotic patients 
are deficient in one or both. It has also been identified that there is a 
reduction in risk of fractures when calcium and Vitamin D are given in 
combination rather than Vitamin D alone [6].
In many countries, the predominant source of calcium and Vitamin D are 
milk, yogurt, cheese, orange juice, and dietary supplements which have 
a positive effect on bone loss and risk of fracture. A study conducted 
by National Osteoporosis Foundation in 120 elderly patients showed 
that the mean total daily calcium intake was 970 mg which included 
686 mg through milk, yogurt, and cheese along with supplementation 
of 284 mg/day [7,8].
A better understanding of this process is possible with the study of drug 
utilization pattern of calcium, Vitamin D, and anti-osteoporosis drugs 
in patients with osteoporotic fractures. Hence, the study was carried 
out with the objective to assess the drug utilization pattern of calcium, 
Vitamin D supplements, and anti-osteoporosis drugs in patients with 
osteoporotic fracture visiting the orthopedic outpatient department in 
a tertiary care teaching hospital.
MATERIALS AND METHODS
A prospective cross-sectional study was conducted in outpatient 
orthopedics department of a tertiary care teaching hospital located in 
Dakshina Kannada, Deralakatte, Mangaluru. The study was carried out 
for 6 months (October 2016–March 2017). This study was approved 
by the Institutional Ethics Committee (REF: INST.EC/EC/112/2016-
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2017). A total of 73 patients of either gender aged 50 years or above 
diagnosed with osteoporotic fracture receiving treatment in the 
outpatient orthopedics department were included in the study. 
Hospitalized orthopedic patients and patients visiting the orthopedics 
department with non-osteoporotic fractures were excluded from the 
study. The patient data collection form was designed as per the need 
of the study. The patient data collection form includes demographic 
details of the patient, complaints on admission, medical and medication 
histories, personal history, social habits, vital signs, diagnosis, adverse 
drug reactions, laboratory parameters, and medication details. All 
the patients visiting the orthopedics department were reviewed on 
daily basis and those who met the study criteria were included in 
the study. All the relevant details including demographics, laboratory 
reports, type of fractures, and the prescribing pattern of the study 
populations have been documented in the data collection form. This 
was continued throughout the study period till the target sample size 
was achieved. The drug therapy of all the patients was analyzed with 
respect to the osteoporotic fractures, receiving calcium, Vitamin D, and 
anti-osteoporosis drugs. This was performed to assess the prescribing 
pattern of calcium, Vitamin D supplements, and anti-osteoporosis drugs 
and also the comorbidities and their treatment and the most common 
type of osteoporotic fractures.
The data collected were compiled, tabulated in Microsoft Excel 
2013, and finally analyzed using statistical package for social science 
version 16.0 for windows. Quantitative variables were described as 
mean ± SD, and categorical variables were described as frequencies and 
percentages.
RESULTS
A total of 73 patients’ prescriptions were reviewed during the 
study period. Considering the gender wise distribution of the study 
population, female predominance (54.8% [n=40]) was noted over 
males (45.2% [n=33]). The average age of the patient was 63.52±11.06 
(mean±SD) years (range: 50–88 years). The age-wise categorization of 
study population shows that 50% of the study population belongs to 
the age group of 50–60 years followed by 23% of age between 61 and 
70 years. The distribution of study population is shown in Table 1.
Pattern of comorbidities
A total of 81 comorbidities were identified from 73 patients during the 
study period. Among them, 27 (36.98%) patients had one comorbidity, 
21 (28.76%) patients had two comorbidities, 11 (15.06%) patients 
had three or more comorbidities, and 14 (19.17%) patients had no 
comorbidities. Considering the pattern of comorbidities among the 
study population, it was found that hypertension (27.16%) was the 
most frequently occurring comorbidities followed by diabetes mellitus 
(18.51%) and coronary artery diseases (14.81%). The pattern of 
comorbidities among the study population is shown in Fig. 1.
Types of fractures
The types of fractures observed were metaphyseal fractures in 61.64% 
of the patients and diaphyseal fractures in 23.28% of the patients. The 
other fractures observed in the patients include mandibular angle 
fracture (1.36%), spine compression fracture (2.72%), Colles’ fracture 
of wrist (2.72%), patella fracture (2.72%), calcaneus fracture (4.08%), 
and compression fracture of dorsal spine (1.36%).
Classification of drugs prescribed
A total of 709 drugs belonging to different classes were prescribed 
during the study period. Nonsteroidal anti-inflammatory drugs 
(NSAIDs) (17.06%) were the most commonly prescribed class of drugs 
followed by antiulcer drugs (14.95%), opioid analgesics (11.56%), and 
anti-infective agents (11.14%). The various class of drugs prescribed in 
patients with osteoporotic fractures is shown in Table 2.
Distribution of calcium and Vitamin D supplementation
Considering the prescribing pattern of calcium and Vitamin D 
supplementation among the study subjects, it was found that majority 
of patients (65.75%) received both calcium and Vitamin D3 in 
their prescription. The anti-osteoporosis drug bisphosphonate was 
prescribed only in 2.73% of the patients and the remaining 31.5% 
of patients were prescribed with neither calcium, Vitamin D, nor 
bisphosphonate in their prescription. The prescribing pattern of 
calcium and Vitamin D3 along with bisphosphonates is shown in Fig. 2.
Dosing of supplemental calcium and Vitamin D supplements
Of the total study population who were prescribed with calcium 
supplementation, 82.92% were taking <500 mg of calcium daily, 
14.63% taking 500–1000 mg, and 2.43% taking >1000 mg of calcium. In 
case of Vitamin D supplementation, 63.01% of patients were prescribed 
with 0.25 µg, 26.02% were prescribed with 60,000 IU, and 1.36% 
were prescribed with 250IU of Vitamin D supplementation. Dosing of 
Vitamin D3 among the study population is shown in Table 3.
DISCUSSION
Osteoporotic fractures are frequent in elderly populations, especially in 
women and are associated with increased morbidity and mortality with 
frequent hospitalization and high health-care expenditure. Hence, there 
is an increased need of studying the different aspects related to bone 
health. For doing so, we have to determine the risk factors associated, 
Table 1: Demographic details of the study populations with 
osteoporotic fractures









Table 2: Drugs coprescribed in osteoporotic fractures
S. No Drugs n=709 (%)
1 NSAIDs 121 (17.06)
2 Antiulcer drugs 106 (14.95)
3 Opioid analgesics 82 (11.56)
4 Anti-infective agents 79 (11.14)
5 Vitamins 75 (10.57)
6 Vitamin D granules 58 (8.18)
7 Pregabalin 46 (6.48)
8 Calcium supplements 44 (6.20)
9 Antihypertensive agents 32 (4.51)
10 Antidiabetic agents 29 (4.09)
11 Cardiovascular agents 16 (2.25)
12 Antiasthma drugs 13 (1.83)
13 Steroids 6 (0.84)
14 Bisphosphonates 2 (0.28)
NSAIDs: Nonsteroidal anti-inflammatory drugs
Fig. 1: Comorbidities among the study population
372
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 370-373
 Augustine et al. 
comorbidities involved, and the drug therapy required for prevention 
and treatment [9,10].
The study result showed that majority of the patients with 
osteoporotic fracture in the age group of 50–60 years with a mean 
age of 63.52±11.06 years. This can be due to the progression of bone 
degradation due to aging as a consequence of higher bone turnover 
rate. Furthermore, the gender distribution showed that females were 
more prone to osteoporotic fractures than male patients. Similar results 
were seen in a study where the majority of patients were women and 
mean age was 67.8 years [11]. This might be due to menopause which 
leads to estrogen deficiency causing bone loss and calcium excretion. 
The cause of bone resorption in males can be explained by the decrease 
in testosterone levels [12].
Majority of the patients in our study showed a predominance of femur 
fractures as compared to other fractures. These findings were similar 
to the previous studies carried out on calcium intake in elderly patients 
with osteoporotic fractures which showed higher incidence of femur 
fractures [13,14].
Various studies have shown that there is an association between 
comorbidities and the risk of fracture with the most prevalent 
comorbidities as diabetes and cardiovascular diseases [15,16]. In our 
study, hypertension, coronary artery disease, and diabetes were found 
to be commonly occurring comorbidities. These comorbid conditions 
are more prevalent in the higher aged individuals, and it interferes 
with the repair mechanism of the body. Furthermore, the drug therapy 
requirements increase along with the other existing diseases. This can 
also prolong the hospitalization, negatively increase the adverse effects 
and increase the financial burden on patients. Because of the increased 
number of drug prescriptions, there may be drug related problems as 
well as diminished efficacy of the drugs used for fracture treatment. 
This significantly affects the quality of life of the patients.
Global strategies for the prevention of fractures involve measures such 
as regular exercise, hip protectors, smoking cessation, reducing alcohol 
consumption, and diet modification. Daily dietary intake of calcium and 
Vitamin D is an important factor in the prevention and treatment of 
osteoporotic fractures. Daily intake of foods which are rich in calcium 
and Vitamin D such as kale, spinach, broccoli, okra, soya bean, sardines, 
salmon, egg yolk, fortified dairy products, orange, and oatmeal is 
necessary to improve bone strength [17]. Selection of an optimal 
therapy proves to be challenging due to the coexisting conditions 
and their treatment. The mainstay of therapy in osteoporotic fracture 
patients is supplementation with calcium and Vitamin D. Calcium 
plays an essential role in maintaining bone health across all ages and 
insufficient intake of calcium negatively affects bone metabolism 
and Vitamin D helps in absorbing the required amount of calcium. 
Bisphosphonates have been proved to be effective in preventing the 
fractures in patients with risk but are not generally used [18].
Calcium and Vitamin D supplementation were prescribed more in 
the patients aged between 50 and 60 years. The prescribed doses of 
calcium and Vitamin D were lower than that recommended in various 
literatures [19,20]. Most of the calcium and Vitamin D preparations 
prescribed were not generic which also adds to the financial burden.
Apart from fracture treatment, it is essential to manage the underlying 
disease and patients’ health status. For pain management, it was noted 
that majority of the patients were prescribed with NSAIDs and opioid 
analgesics. These findings were similar to the results of a previous study 
which showed that NSAIDs were prescribed in 97% of the patients [21]. 
Paracetamol and diclofenac were the most commonly used painkillers 
for the treatment of mild-moderate pain, and tramadol was used for 
severe pain. Furthermore, anti-inflammatory enzymes, i.e., trypsin and 
chymotrypsin with or without diclofenac were found to be used in most 
of the patients. In our study, most of the patients received antibiotics 
for the management of post-operative fracture-associated infections. 
Among the antibiotics prescribed, the third-generation cephalosporins 
were given more frequently. The choice of antibiotics must be based 
on the most likely pathogen at the site of the infection, and it is always 
better to carry out the culture/sensitivity tests so as to prevent the 
irrational use of antibiotics and the emergence of drug resistance.
Majority of the prescriptions were coprescribed with proton-pump 
inhibitors (PPIs) (80.82%) (Pantoprazole) as compared to histamine-2 
receptor antagonists (H2RA) (ranitidine) to minimize drug induced 
gastritis associated with antibiotics, NSAIDs, and opioid analgesics. Our 
study results were inconsistent with other studies which showed that 
H2RA were the most commonly coprescribed to minimize drug-induced 
gastritis [22,23].
Even though PPIs produce more sustained acid suppression and 
promote ulcer healing, substitution with other gastrointestinal 
protective agents such as antacids and ranitidine may potentially yield 
substantial cost savings. The patient education and knowledge about 
medicines will help to improve adherence and is considered vital for 
preventing and management of osteoporosis-related fractures.
CONCLUSION
The study shows the pattern of different types of osteoporotic fractures 
in geriatric patients and the drug use among them. Considering that 
calcium and Vitamin D supplementation are essential for the treatment 
of osteoporosis, regular monitoring of serum calcium and Vitamin 
D3 levels should be put into health-care practice more widely so that 
Fig. 2: Prescribing pattern of calcium, Vitamin D3, and 
bisphosphonates
Table 3: Dosing of calcium and vitamin D in study populations
Age group (y) Number of patients
Calcium (mg/day) Vitamin D
<500 500–1000 >1000 0.25 µg/day 250 IU/day 60 kIU/week
50–60 16 3 0 24 0 7
60–70 12 1 0 13 0 5
70–80 3 1 1 5 1 5
80–90 3 1 0 4 0 2
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the daily dose of calcium and Vitamin D3 can be tailored according 
to the individual needs. The patient education lifestyle and dietary 
supplements play a very important role in the management of 
osteoporosis; further, efforts should be taken to increase the adherence 
of calcium, particularly in osteoporotic fractures.
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